BUR vs MBIN

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of just 3/9 indicating weak financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong profitability margins and a low Price/Book ratio, the company faces severe revenue contraction (YoY growth of -73.60%) and deeply negative earnings surprises, with 11 of the last 12 quarters missing or drastically underperforming estimates. While the stock trades below the Graham Number of $10.01, suggesting slight undervaluation, the weak fundamentals, deteriorating growth, and lack of insider support undermine this. The strong_buy analyst consensus appears overly optimistic given the deteriorating operational performance and bearish technical trend.

MBIN exhibits a severe divergence between its recent price performance and its fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the stock is trading below its Graham Number ($56.61), it is significantly overpriced relative to its growth-based intrinsic value ($26.46). Negative year-over-year revenue (-17.60%) and earnings growth (-30.60%) suggest a deteriorating business model, further compounded by bearish insider selling from the CEO. The recent price rally appears disconnected from the underlying financial decay.